Tirzepatide vs Semaglutide: Pros and Cons

Tirzepatide and semaglutide are both injectable medications used for weight loss and type 2 diabetes management, but they differ in their mechanisms of action and effectiveness. Here's a comparison of the two drugs:

Mechanism of Action​

Tirzepatide:

• Dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist
• Activates both GIP and GLP-1 receptors

Semaglutide:

• Selective GLP-1 receptor agonist
• Activates only GLP-1 receptors

Effectiveness for Weight Loss​

Tirzepatide:

• Associated with greater weight loss compared to semaglutide
• In a study of adults with overweight or obesity:
  • Patients were 1.76 times more likely to achieve ≥5% weight loss
  • 2.54 times more likely to achieve ≥10% weight loss
  • 3.24 times more likely to achieve ≥15% weight loss compared to semaglutide

Semaglutide:

• Effective for weight loss, but generally less so than tirzepatide
• Approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition

Effectiveness for Type 2 Diabetes​

Both medications are effective in treating type 2 diabetes, but tirzepatide has shown superior results:Tirzepatide:

• In a 40-week trial, tirzepatide at doses of 5 mg, 10 mg, or 15 mg was superior to semaglutide 1 mg in reducing glycated hemoglobin levels
• 82-86% of patients reached the target glycated hemoglobin level of <7.0%

Semaglutide:

• Effective in lowering blood sugar levels in adults with type 2 diabetes
• 79% of patients reached the target glycated hemoglobin level of <7.0% in the same trial

Dosage and Administration​

Tirzepatide (Zepbound):

• Weekly subcutaneous injection
• Dosage increased over 4-20 weeks to target doses of 5 mg, 10 mg, or 15 mg

Semaglutide (Wegovy):

• Weekly subcutaneous injection
• Typical dose for weight loss is 2.4 mg

Side Effects​

Both medications have similar side effect profiles, with gastrointestinal issues being the most common:

• Nausea
• Diarrhea
• Vomiting
• Constipation
• Abdominal discomfort

Considerations​

• Tirzepatide is a newer medication, approved by the FDA in November 2023 for chronic weight management
• Semaglutide has been in use longer and has more established safety data
• Both medications should be used in conjunction with diet and exercise for optimal results
• Neither medication is recommended for patients with a history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2

In conclusion, while both tirzepatide and semaglutide are effective medications for weight loss and type 2 diabetes management, current evidence suggests that tirzepatide may be more effective in achieving weight loss and glycemic control. However, the choice between the two should be made in consultation with a healthcare provider, considering individual patient factors, medical history, and treatment goals.

Citations:
[1] Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity
[2] FDA Approves New Medication for Chronic Weight Management
[3] Medications Containing Semaglutide
[4] https://www.nejm.org/doi/full/10.1056/NEJMoa2107519
[5] Tirzepatide (Subcutaneous Route) Description and Brand Names - Mayo Clinic
[6] Semaglutide, also known as Ozempic, for weight loss - what you need to know

 

Semaglutide May Reduce Alcohol Consumption in Patients With AUD​

May 5, 2026
A randomized controlled trial of 108 adults with alcohol use disorder (AUD) and obesity found that weekly semaglutide injections significantly reduced heavy drinking days compared to placebo over 26 weeks. Participants receiving semaglutide also showed improvements in alcohol consumption, cravings, and metabolic measures. The study highlights the potential of GLP-1 receptor agonists (RAs) as a novel treatment for AUD. However, further research is needed to confirm these findings in populations without obesity. The study was funded by the Research Foundation, Mental Health Services (Capital Region of Denmark), Novo Nordisk Foundation, Novavi Foundation, Hartmann Foundation, and the Augustinus Foundation.

 

Semaglutide May Reduce Alcohol Consumption in Patients With AUD​

May 5, 2026
A randomized controlled trial of 108 adults with alcohol use disorder (AUD) and obesity found that weekly semaglutide injections significantly reduced heavy drinking days compared to placebo over 26 weeks. Participants receiving semaglutide also showed improvements in alcohol consumption, cravings, and metabolic measures. The study highlights the potential of GLP-1 receptor agonists (RAs) as a novel treatment for AUD. However, further research is needed to confirm these findings in populations without obesity. The study was funded by the Research Foundation, Mental Health Services (Capital Region of Denmark), Novo Nordisk Foundation, Novavi Foundation, Hartmann Foundation, and the Augustinus Foundation.

I have yet to pull the trigger on these peptides. I have Nafld but Ive been taking 40 grams resitance startch, lifting, cardio and cleaning up my diet. Also sprinkling in tesamorelin for 6 months. Might go the full year.
Maybe I just don't want to become emaciated